Dual payload antibody drug conjugate - Suzhou GeneQuantum Healthcare
Latest Information Update: 23 Jun 2024
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Jun 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical study in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR- 2024)
- 14 Apr 2023 Preclinical trials in Cancer in China (Parenteral) (before April 2023)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR- 2023)